| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000008768 |
| Receipt No. | R000010306 |
| Official scientific title of the study | An randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients with cancer |
| Date of disclosure of the study information | 2012/08/25 |
| Last modified on | 2017/02/27 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | An randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients with cancer | |
| Title of the study (Brief title) | An randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients | |
| Region |
|
|
| Condition | ||
| Condition | Majar depression in cancer patient | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect of mirtazapine or duloxetine hydrochloride on the depressive symptoms in patients with cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Change in HAM-D scores between pretreatment baseline and 6-week treatment |
| Key secondary outcomes | Specific symptoms (pain and nausea)
Adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | antidepressants | |
| Interventions/Control_2 | safety | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Age >= 20 years old
2)Possible oral administration 3)Patient with any cancer 4)Male or female. Inpatient or outpatient. 5)Written informed consent |
|||
| Key exclusion criteria | 1)Brain metastasis confirmed
2)Congnitive impairment 3)Under interferon therapy 4)Bipolar disorder 5)Convulsive disorder or history of convulsive disorder 6)Prior electroconvulsive therapy 7)Dysuria, glaucoma or treatment for elevated intraocular pressure 8)Administration of the monoamine oxidase (MAO) inhibitor within observation period(2 weeks) 9)Hypersensitivity to mirtazapine or duloxetine hydrochloride 10)Pregnancy or lactating woman, woman planning pregnancy 11)Substance or alcohol abuse 180 days prior to administration of investigational drug. 12)Patient ineligible to the study based on investigator's decision. |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Nishimura ryouji |
| Organization | Fukuoka University Faculty of Medicine |
| Division name | Department of Psychiarty |
| Address | 7-45-1, Nanakuma, Johnan-ku, Fukuoka, 814-0180, Japan |
| TEL | 092-801-1011 |
| Public contact | |
| Name of contact person | Matsushita michihiko |
| Organization | Fukuoka University Faculty of Medicine |
| Division name | Department of Psychiarty |
| Address | 7-45-1, Nanakuma, Johnan-ku, Fukuoka, 814-0180, Japan |
| TEL | 092-801-1011 |
| Homepage URL | |
| matsushita@fukuoka-u.ac.jp | |
| Sponsor | |
| Institute | Fukuoka University Faculty of Medicine Department of Psychiarty |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 福岡大学病院(福岡県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000010306 |